FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to novel derivatives of 2-oxo-1-pyrrolidine of the formula (I) 
or their pharmaceutically acceptable salts wherein X means -CA1NR5R6 or -CA1-R8 wherein A1 and A2 mean independently oxygen atom; R1 means hydrogen atom (H), (C1-C20)-alkyl, (C6-C10)-aryl or -CH2-R1a wherein R1a means (C6-C10)-aryl; R3 means H, -NO2, nitrooxy-group, C≡N, azido-group, -COOH, amido-group, (C1-C20)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl, (C6-C10)-aryl, thiazolyl, oxazolyl, furyl, thienyl, pyrrolyl, tetrazolyl, pyrimidinyl, triazolyl, pyridinyl, -COOR11, -COR11 wherein R11 means (C1-C12)-alkyl; R3a means H, (C1-C20)-alkyl, (C2-C6)-alkenyl, (C2-C6)-alkynyl or (C6-C10)-aryl; R5 and R6 are similar or different and each means independently H, (C1-C6)-alkyl, and R8 means -OH and wherein each alkyl can be substituted independently with from 1 to 5 substitutes chosen from halogen atom, isothiocyanate, -OH, -NO2, -CN, azido-group, (C3-C6)-cycloalkyl and (C6-C10)-aryl;, and wherein each (C6-C10)-aryl can be substituted independently with from 1 to 5 substitutes chosen from halogen atom, -NH2, -NO2, azido-group, (C1-C6)-alkoxy-group, (C1-C6)-alkyl and (C1-C6)-halogenalkyl, and wherein each alkenyl can be substituted independently with at least one substitute chosen from halogen atom and -OH, and under condition that at least one radical among R and R3a differs from H, and when compound represent a mixture of possible isomers then X means -CONR5R6; A2 means oxygen atom, and R1 means H, -CH3, -C2H5, -C3H7, and when each R1 and R3a means H and A2 means oxygen atom and X means -CONR5R6 then R3 differs from -COOH, -CH, -COOR11, amido-group, naphthyl, phenyl rings substituted with (C1-C6)-alkoxy-group or halogen atom in para-position in naphthyl or phenyl ring. Compounds of the formula (I) can be used in pharmaceutical compositions for treatment of epilepsy, epileptogenesis, convulsions, epileptic seizures, essential tremor and neuropathic pain.
EFFECT: improved method of synthesis, valuable medicinal properties of derivatives and pharmaceutical compositions.
27 cl, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS | 2012 |
|
RU2665021C2 |
| METHODS AND COMPOSITIONS TO IMPROVE COGNITIVE FUNCTIONS | 2012 |
|
RU2792010C2 |
| DERIVATIVES OF DOLAPROIN-DOLAIZOLEIN PEPTIDES | 2015 |
|
RU2747989C2 |
| SYNTHETIC INTERMEDIATE COMPOUND 1-(2-DESOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE THIONUCLEOSIDES COMPOUND AND METHOD FOR THEIR PRODUCTION | 2013 |
|
RU2633355C2 |
| DERIVATIVES OF 2-OXO-1-PYRROLIDINE, METHODS FOR THEIR PREPARING AND USING | 2001 |
|
RU2292336C2 |
| FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS AND USE THEREOF | 2017 |
|
RU2732127C1 |
| NMDA RECEPTOR MODULATORS AND THEIR APPLICATION | 2012 |
|
RU2621049C2 |
| PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
| AMINOPYRAZOLOPYRIMIDINE COMPOUND USED AS INHIBITOR OF TYROSINE KINASE RECEPTOR OF NEUROTROPHIC FACTOR | 2017 |
|
RU2764523C2 |
| N-(2-BENZYL)-2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | 2005 |
|
RU2378255C2 |
